title: Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.
abstract: Annexin A3 (ANXA3) has been found to play important roles in cancer progression, metastasis, and drug resistance; however, its role in hepatocellular carcinoma (HCC) remains unknown. In this study, we investigated the expression level, clinical significance and biologic function of ANXA3 in HCC. Real-time quantitative reverse transcriptase-polymerase chain reaction, western blotting and immunohistochemical staining were used to examine ANXA3 expression levels in HCC tumor tissue, and its correlation with the clinicopathological features and prognosis of HCC patients was analyzed. The biological functions of ANXA3 in cell proliferation, migration, invasion, and resistance to chemotherapy were also investigated. ANXA3 expression was significantly increased in HCC tissues as compared with adjacent non-tumorous tissues. Elevated ANXA3 expression was associated with tumor size, number of lesions, tumor stage, and poor prognosis. In hepatoma cell lines, exogenous ANXA3 transduction promoted the tumorigenic activity and metastatic potential of tumor cells. Small interfering RNA silencing of ANXA3 inhibited these processes. In addition, in vitro and in vivo experiments revealed that ANXA3 overexpression enhanced resistance to chemotherapy. Taken together, our findings reveal that ANXA3 might play an important role in HCC progression and chemoresistance, and could serve as a novel prognostic marker and therapeutic target for HCC.
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Qiu-Zhong
authors.initials: QZ
authors.lastname: Pan
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Ke
authors.initials: K
authors.lastname: Pan
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: De-Sheng
authors.initials: DS
authors.lastname: Weng
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Jing-Jing
authors.initials: JJ
authors.lastname: Zhao
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Xiao-Fei
authors.initials: XF
authors.lastname: Zhang
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Wang
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Lin
authors.initials: L
authors.lastname: Lv
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Jiang
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Hai-Xia
authors.initials: HX
authors.lastname: Zheng
authors.affiliation: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.|Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
authors.forename: Jian-Chuan
authors.initials: JC
authors.lastname: Xia
mesh_terms: D000328:Adult; D017318:Annexin A3 / Q000235:genetics* / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015854:Up-Regulation
chemical_list: D017318:Annexin A3
keywords: 5-fluorouracil; ANXA3; cisplatin; hepatocellular carcinoma; prognosis